雜志介紹

Expert Opinion On Biological Therapy雜志介紹

《Expert Opinion On Biological Therapy》是一本以English為主的未開放獲取國際優(yōu)秀期刊，中文名稱生物治療專家意見，本刊主要出版、報(bào)道醫(yī)學(xué)-BIOTECHNOLOGY & APPLIED MICROBIOLOGY領(lǐng)域的研究動(dòng)態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗(yàn)和科研成果，介紹該領(lǐng)域有關(guān)本專業(yè)的最新進(jìn)展，探討行業(yè)發(fā)展的思路和方法，以促進(jìn)學(xué)術(shù)信息交流，提高行業(yè)發(fā)展。該刊已被國際權(quán)威數(shù)據(jù)庫SCIE收錄，為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動(dòng)作用，也得到了本專業(yè)人員的廣泛認(rèn)可。該刊最新影響因子為3.6，最新CiteScore 指數(shù)為8.6。

本刊近期中國學(xué)者發(fā)表的論文主要有：

• Recent advances in stem cell therapy for erectile dysfunction: a narrative review

  Author: Wang, Bohan; Gao, Wenjun; Zheng, Micha Y.; Lin, Guiting; Lue, Tom F.

• Comparing the pharmacokinetics, safety, and immunogenicity of HLX02 to US- and EU-approved trastuzumab in healthy Chinese male subjects: A Phase I, randomized, double-blind, parallel-group study

  Author: Zhou, Wenjia; Wang, Meng; Yu, Yunli; Wang, Ji; Wu, Yanni; Yang, Guiyu; Yu, Haoyu; Li, Jing; Zhou, Liang; Zhang, Quanying

• Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomized, double-blind, single-dose, parallel-controlled trial

  Author: Guo, Yinhan; Guo, Tingting; Di, Yujing; Xu, Wenyu; Hu, Zhitian; Xiao, Yanfeng; Yu, Heze; Hou, Jie

• Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects

  Author: Zhang, Qin; Sun, Cheng; Wu, Jinying; Wu, Juan; Zhang, Xuan; Liu, Yueyue; Dou, Changlin; Qin, Huilin; Zhang, Qian; Zhou, Renpeng; Hu, Wei

英文介紹

Expert Opinion On Biological Therapy雜志英文介紹

Expert Opinion on Biological Therapy (1471-2598; 1744-7682) is a MEDLINE-indexed, international journal publishing peer-reviewed research across all aspects of biological therapy.

Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development.

The audience consists of scientists and managers in the healthcare and biopharmaceutical industries and others closely involved in the development and application of biological therapies for the treatment of human disease.

The journal welcomes:

Reviews covering therapeutic antibodies and vaccines, peptides and proteins, gene therapies and gene transfer technologies, cell-based therapies and regenerative medicine

Drug evaluations reviewing the clinical data on a particular biological agent

Original research papers reporting the results of clinical investigations on biological agents and biotherapeutic-based studies with a strong link to clinical practice

Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections:

Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results;

Article Highlights – an executive summary of the author’s most critical points.